Stockreport

FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer

IMMUNOMEDICS  (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
PDF First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment [Read more]